Introduction The cost of cancer treatment has progressively increased over the past decade as newer chemotherapy and immunotherapy agents have been established. Glioblastoma, in particular, has a significant cost in the health care system because of both the severity of…
The prognosis following diagnosis of glioblastoma remains poor. Historically, there have been many notable attempts to use local drug delivery to treat glioblastoma, including convection-enhanced delivery (CED), direct tumor injection, and the use of to deliver chemotherapeutics. The use of…
Given the aggressive nature of glioblastoma, it is nearly a certainty that all patients will need to be evaluated for potential treatment of recurrent disease. There is currently no definitive standard of care for recurrent glioblastoma. Unlike in other solid…
Introduction With an incidence of 3 to 5 per 100,000, glioblastoma fulfills the criteria of a rare cancer. Despite this, glioblastoma is the most common and most aggressive primary brain tumor and accounts for 12% to 15% of all intracranial…
The cellular origin of glioblastoma is complex. Despite decades of research, the understanding of the cellular, molecular, and pathogenetic architecture of this lethal disease is still evolving. Other chapters discuss the epidemiology, risk factors, associated clinical outcomes, and molecular targeting…